Trim 30-40% at resistance; replace broken $235.40 stop with $200 hard invalidation
Bearish direction is empirically correct on all three analyst axes (bear-market-rally technical setup, structural fundamental impairment from collapsed buybacks and negative operating leverage, hostile macro with 85% probability of zero Fed cuts through 2026 and Zacks/Truist confirming HD share gains). However, the trader's SELL label over-commits at $220: valuation cushion is real (16x forward P/E, 6.2% FCF yield, 3.6x dividend coverage), 50 SMA is holding, and the 08-18 lesson explicitly warned against bearish over-commitment at technical floors. Override SELL label to Underweight per 08-17 lesson. Execute 30-40% trim (Neutral midpoint) into current $218-220 zone and $220-225 relief rallies; do NOT wait for $226+ entry which sits at confirmed resistance ($226.18 intraday rejection). Replace broken $235.40 stop with $200 hard invalidation (July swing low, consistent with $199 price target) and $213 early-warning on 50 SMA break with volume >2.5M. Skip hedge per elevated IV lesson. Re-engage only on volume-validated reclaim of 200 SMA, in-line/better Q3 print with margin stabilization, or HD guide-up. Explicitly rejected: HD/LOW pair trade (basis risk, dual execution), waiting for $226+ entry (resistance, not support), full Sell at $218-220 (30-40% trim dressed in stronger language).
| Position | Action |
|---|---|
| Current $218-220 zone or relief rally $220-225 | Trim 30-40% total position over 1-2 sessions |
| Immediate execution | Stage ~20% immediately |
| Relief rally $220-225 | Scale in additional 10-20% |
| Post-trim residual position | Sell Aug $240 call against ~1/3 of residual to monetize elevated IV premium |
| Full exit trigger | Close below $199.40 July low on volume >2.5M |
LOW has formed a technical bottom following a 31% drawdown to $199.40, with momentum confirming a reversal while fundamentals show Q1 FY2027 reacceleration to +10.3% YoY revenue growth and a compelling valuation of 16.5x forward earnings with 6.2% FCF yield.
| Indicator | Value | Signal |
|---|---|---|
| close | 220.00 | neutral |
| open | 217.00 | neutral |
| high | 225.79 | neutral |
| low | 212.50 | neutral |
| volume | 4,956,178 | neutral |
| 10_ema | 217.47 | bullish |
| 50_sma | 215.15 | bullish |
| 200_sma | 235.41 | bearish |
| rsi | 55.16 | neutral |
| macd_line | 1.42 | bullish |
| macd_signal | 1.17 | bullish |
This report is AI-generated for informational and educational purposes only and is not investment advice or a recommendation to buy or sell any security. Full disclaimer.
When: In-line or better Q3 FY26 print with constructive FBM synergy commentary AND margin stabilization
Then: Re-evaluate to Hold or Buy
A structured upside trade targets $235.41 with defined risk at $213.50, offering favorable reward-to-risk.
EV: +7.5% · concedes: Persistent downtrend with lower lows and lower highs occurred until July 23; Price remains 6.5% below 200 SMA; Q2 revenue missed expectations; FY guidance was narrowed to bottom of prior range; DIY weakness is real in the near term; Negative equity reflects $40B+ in historical buybacks (optical only)
LOW's technical "reversal" is a bear market relief rally; fundamentals are deteriorating with Q2 revenue missing by ~$200M, comps decelerating to +0.2%, and the $8.7B acquisition adding 460% goodwill and 17% leverage without clear strategic value; macro headwinds persist with Fed on hold, oil +36% YTD, and DIY consumer structurally weakening.
EV: $199.40 (cycle low retest) · concedes: Dividend is safe at 2.32% yield with 3.6x FCF coverage; Valuation is not extremely stretched on an absolute basis; 199.40 is a real cycle low (potential floor if confirmed); Q2 EPS did technically beat consensus; Current price is near the bottom of the range, limiting near-term downside if fundamentals stabilize
→ vs conservative: Dividend yield rising because price is falling, not because dividend is safe - this is a falling knife dressed in dividend clothing; FY2026 revenue still below FY2023 peak; management buyback collapse ($14.1B to $211M) signals insider lack of confidence; FCF coverage doesn't address the price trajectory
→ vs neutral: Waiting for confirmation at $215 break means giving back $5+ first and potentially retesting the $199.40 cycle low; today's candle IS the confirmation - a bull trap at upper Bollinger with closing reversal is one of the most bearish signals in weeks; by the time Q3 prints in November, additional drawdown will have occurred
| macd_histogram | 0.25 | bullish |
| boll_mid | 215.45 | neutral |
| boll_upper | 226.18 | bearish |
| boll_lower | 204.72 | bullish |
| boll_percent_b | 0.71 | neutral |
| atr | 6.00 | neutral |
| vwma | 216.74 | bullish |
Support: 215.15 · 210 · 204.72 · 199.4 | Resistance: 226.18 · 235.41 · 244 · 245
Lowe's technicals show a conflicted picture: short-term momentum is bullish (MACD positive cross, price above 50 SMA and 10 EMA, VWMA confirming the rally from 199.40 cycle low), but the long-term trend remains firmly bearish (price below declining 200 SMA at 235.41, lower-low/lower-high structure intact since Feb 2026 peak at 289.87). RSI at 55.16 provides room for upside without overbought risk, while ATR at 6.00 indicates stable volatility. The immediate tactical range is 215–226, with 235.41 as the strategic resistance ceiling; a close above 226.18 on above-average volume would be needed to challenge the 200 SMA. Recommendation is HOLD/Neutral with a bullish tactical lean—existing holders can hold with a 213.50 stop, new positions should await breakout confirmation above the upper Bollinger band.
Market Cap
$123.36 B
TTM PE Ratio
18.58x
Forward PE
16.48x
PEG Ratio
1.40
Price-to-Book
-13.31x
52-Week High
$293.06
52-Week Low
$199.40
50-Day Average
$215.68
200-Day Average
$237.82
Beta
0.851
Dividend Yield
2.32%
Diluted EPS (TTM)
$11.84
Forward EPS
$13.35
Revenue FY2026
$86.29 B
Revenue YoY (FY2026)
+3.1%
Net Income FY2026
$6.65 B
Net Income YoY (FY2026)
-4.4%
Diluted EPS FY2026
$11.85
Q1 FY2027 Revenue
$23.08 B
Q1 FY2027 Revenue YoY
+10.3%
Q1 FY2027 Operating Income
$2.554 B
Q1 FY2027 Operating Margin
11.1%
Q1 FY2027 Net Income
$1.628 B
Q1 FY2027 Diluted EPS
$2.90
Gross Margin (TTM)
33.3%
Net Margin (TTM)
7.5%
ROA
12.8%
Total Assets
$54,941 M
Total Liabilities
$64,211 M
Stockholders' Equity
-$9,270 M
Long-Term Debt
$36,751 M
Net Debt
$37.2 B
Debt/EBITDA
~2.4x
Current Ratio
1.09
Inventory
$18,447 M
Goodwill & Intangibles
$9,752 M
Operating CF (FY2026)
$9.86 B
Free CF (FY2026)
$7.65 B
FCF/Dividend Coverage
3.6x
Dividends Paid FY2026
$2.64 B
Buybacks FY2026
$211 M
Q1 FY2027 Operating CF
$3.35 B
Q1 FY2027 Free CF
$2.83 B
Q1 FY2027 Buybacks
$363 M
Q1 FY2027 Debt Repaid
$2.38 B
Acquisition Completed Q3 FY2026
~$8.7 B
Interest Expense FY2026
$1.5 B
Revenue 3-Year CAGR
~-3.8%
Strengths
Concerns
Lowe's is a mature, high-quality, cash-generative home improvement retailer with fundamentally sound operations — gross margins at 33%, FCF of $7.65B, and dividend coverage of 3.6x. However, the company faces a challenging top-line environment (revenues down from FY2023 $97B peak to ~$86B) and has taken on significant debt (net debt $37.2B, Debt/EBITDA ~2.4x) for an ~$8.7B acquisition in Q3 FY2026. Early Q1 FY2027 signs of revenue reacceleration (+10.3% YoY) are encouraging but require confirmation. The stock is cautiously neutral — attractive for income investors at current levels, but momentum traders should wait for a break above the 200-day MA ($237.82). Key catalysts include Q2 FY2027 earnings, mortgage rate trajectory, and integration progress of the major acquisition.
Macro: Fed on hold with 85% implied probability of zero rate cuts in 2026; FOMC minutes showed most participants support holding rates. US recession odds at 8% (low) — supportive for consumer discretionary. US Treasury expanded long-dated bond buybacks, driving 10Y yields sharply lower — direct positive for housing-adjacent equities. Oil +36% YTD with Strait of Hormuz closed; geopolitical risk premium elevated. Japan recession odds at 31% (+3pp WoW); UK recession odds at 10% (down 9pp WoW). S&P 500, Nasdaq, Dow all green on Fed minutes + Treasury buyback expansion. Capital rotating into biopharma (Moderna, Merck).